Author

Xuejun Liu

Observed name: Xue-Jun Liu

Institutions: Shanxi Medical University, First Hospital of Shanxi Medical University

Observed institutions: Shanxi Medical University, Affiliated Hospital of Qingdao University, First Hospital of Shanxi Medical University, Janssen Research & Development (United States)

ORCID: 0000-0001-8194-3067

Observed ORCID: 0000-0001-8194-3067

OpenAlex ID: A5100740295

Comparison of RNA-Seq and Microarray in Transcriptome Profiling of Activated T Cells

2014 · Shanrong Zhao, Wai-Ping Fung-Leung, et al. · PLoS ONE · 1,000

PDF

Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation

2014 · Pejman Soroosh, Jiejun Wu, et al. · Proceedings of the National Academy of Sciences · 254

Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer

2020 · Jared Liu, Hsin-Wen Chang, et al. · Journal of Allergy and Clinical Immunology · 147

RORγt and RORα signature genes in human Th17 cells

2017 · Glenda Castro, Xuejun Liu, et al. · PLoS ONE · 143

PDF

CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression

2017 · Yanxia Guo, Alice M Walsh, et al. · The Journal of Immunology · 130

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

2019 · Kenneth B. Gordon, April W. Armstrong, et al. · Journal of Investigative Dermatology · 110

PDF

A highly efficient, high-throughput lipidomics platform for the quantitative detection of eicosanoids in human whole blood

2012 · Jiao Song, Xuejun Liu, et al. · Analytical Biochemistry · 61

Is There a Correlation between the Presence of a Spiculated Mass on Mammogram and Luminal A Subtype Breast Cancer?

2016 · Song Liu, Xiao-Dong Wu, et al. · Korean Journal of Radiology · 37

PDF

Time Course of Renal Proximal Tubule Injury, Reversal, and Related Biomarker Changes in Rats Following Cisplatin Administration

2013 · James Eric McDuffie, Jing Ying Ma, et al. · International Journal of Toxicology · 37

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors

2025 · Geoffrey Ku, Lin Shen, et al. · Clinical Cancer Research · 25

PDF

Automatic Analysis of Quantitative NMR Data of Pharmaceutical Compound Libraries

2012 · Xuejun Liu, Michael X. Kolpak, et al. · Analytical Chemistry · 18

T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers

2017 · Wai-Ping Fung-Leung, Wilson Edwards, et al. · PLoS ONE · 16

PDF

Phenotyping drug polypharmacology via eicosanoid profiling of blood

2015 · Jiao Song, Xuejun Liu, et al. · Journal of Lipid Research · 13

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy

2024 · Andrew Blauvelt, Yanqing Chen, et al. · JID Innovations · 9

PDF

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

2024 · Andrew Blauvelt, Richard G. Langley, et al. · JID Innovations · 6

METTL14-mediated m 6 A modification of DDIT4 promotes its mRNA stability in aging-related idiopathic pulmonary fibrosis

2025 · Dan Li, Li Qian, et al. · Epigenetics · 3

Supplementary Figure 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors

2025 · Geoffrey Ku, Lin Shen, et al. · 1

Supplementary Table 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors